DISCOUNT-OPTIONSSCHEIN - AMGEN | Real-time BOERSE MUENCHEN 07:45:25 2024-06-21 EDT | ||
| 0.71 EUR | +1.43% |
|
| Current month | +9.38% | ||
| 1 month | -19.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 0.71 | +1.43% |
| 24-06-20 | 0.7 | +12.90% |
| 24-06-19 | 0.62 | +1.64% |
| 24-06-18 | 0.61 | +10.91% |
| 24-06-17 | 0.55 | +19.57% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 07:45 am
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC9YKQ |
| ISIN | DE000HC9YKQ4 |
| Date issued | 2023-10-17 |
| Strike | 320 $ |
| Maturity | 2024-09-18 (90 Days) |
| Parity | 10 : 1 |
| Emission price | 0.83 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.22 € |
|---|---|
| Lowest since issue | 0.27 € |
| Spread | 0.07 € |
| Spread % | 8.86% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.9
USD
Average target price
316.4
USD
Spread / Average Target
+2.11%
- Stock Market
- Certificates
- Certificat
